Clinical trials: Antipsychotic
Schizophrenia, Psychotic Disorders
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an…
- Trial name
- PAFIP3_1Y (NCT02532491)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649 on symptom severity in persons with schizophrenia or schizoaffective disorder.
- Trial name
- NCT00690274
- Testing
- BF2.649
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Youth Treated With Second-generation Antipsychotics
SGA-induced Metabolic Syndrome in Bipolar Youth
The investigators tested the hypothesis that long-chain omega-3 (LCn-3) fatty acid supplementation will attenuate the adverse cardiometabolic effects of second-generation antipsychotics exposure in first-episode adolescent manic…
- Trial name
- NCT01858948
- Testing
- Omega, Quetiapine fumarate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Cincinnati
Eating Disorders
Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
This study will evaluate the effectiveness of the antipsychotic medication olanzapine in treating outpatients with anorexia nervosa.
- Trial name
- NCT00692185
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
One Year Drug Treatment in First-Episode Schizophrenia
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
- Trial name
- NCT00159081
- Testing
- Haloperidol, Risperidone (drug)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine
No Guts No Glory Probiotics
The goal of this clinical trial is to learn if probiotics work to prevent or reduce metabolic side effects caused by antipsychotic medication in adults.
- Trial name
- NGNGP (NCT07606014)
- Testing
- Probiotic Formula
- Where
- 3 sites in Netherlands
- Volunteers
- 112 people
- Sponsor
- University Medical Center Groningen
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
The purpose of this study is to examine whether olanzapine, compared to risperidone, can provide more adequate and timely control of behavioral agitation in acutely ill subjects with schizophrenia.
- Trial name
- NCT00485498
- Testing
- Olanzapine Hydrochloride, Risperidone
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Schizophrenia
Optimisation of Antipsychotic Drug Use in Older People
Drugs such as amisulpride, known as antipsychotic drugs, are used to treat troublesome and distressing symptoms in older people.
- Trial name
- NCT01454453
- Testing
- Patients- dose titration
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- Institute of Psychiatry, London
Cardiovascular Diseases (CVD), Depression Anxiety Disorder
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
Psycho-Cardiological Disease studies the complex links between the cardiovascular system and emotions. The two diseases are now the focus of public health organizations, forming a vicious circle of mutual influence.
- Trial name
- NCT07025590
- Testing
- Moderate-intensity continuous movement and Antipsychotics intervention, Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Guangdong Provincial People's Hospital
Drug-induced Extrapyramidal Side Effects
Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics
The project is aimed at addressing the fundamental issue in antipsychotic therapeutics -the balance between mental state benefits and neurological risks.The latter cannot be overestimated and clinical skills in themselves are…
- Trial name
- NCT02366897
- Testing
- Manus Sensor Pen
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Edinburgh
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
This randomized, multi-center double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235559
- Testing
- bitopertin [RO4917838] level 1, bitopertin [RO4917838] level 2
- Where
- 90 sites in United States, Bulgaria and 5 more
- Volunteers
- 604 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Schizoaffective Disorder
As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations
The purpose of this study is to compare the steady-state pharmacokinetics of paliperidone after oral administration of 15 mg extended-release (ER) OROS paliperidone once daily with the steady-state pharmacokinetics of…
- Trial name
- NCT00796185
- Testing
- Paliperidone ER
- Volunteers
- 62 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Lurasidone Cardiotoxicity, Schizophrenia Patients
Effects of Lurasidone on Left Ventricle Systolic Functions
The goal of our study to learn if lurasidone molecule which is used on patients with schizophrenia or bipolar disorder has any cardiotoxic effect.
- Conditions
- Lurasidone Cardiotoxicity, Schizophrenia Patients, Bipolar Disorders
- Trial name
- Lurasidone (NCT06695676)
- Testing
- Global Longitudinal Strain
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
Major Depressive Disorder With Psychotic Features
Study of Pharmacotherapy of Psychotic Depression
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
- Trial name
- STOP-PD (NCT00056472)
- Testing
- Olanzapine, Sertraline
- Where
- 4 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Weill Medical College of Cornell University
Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy
Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia
Functional dyspepsia (FD) is a common gastrointestinal disease, which is associated with decreased life quality and increased medical cost.
- Conditions
- Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug
- Trial name
- NCT06756139
- Testing
- cognitive behavioural therapy mobile application, Flupentixol and Melitracen Tablets
- Where
- 7 sites in China
- Volunteers
- 88 people
- Sponsor
- Air Force Military Medical University, China
Schizophrenia
Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia
Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia
- Trial name
- TAAS (NCT02040883)
- Testing
- Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole, Tandospirone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qingyun Yin
Weight Gain, Antipsychotic Agents
Clozapine Induced Weight Gain
Clozapine is prescribed to patients with psychosis in whom other treatments have not worked. Research has shown, however, that clozapine may be associated with weight gain and abnormal blood sugar levels in some patients.
- Conditions
- Weight Gain, Antipsychotic Agents, Pharmacogenetics
- Trial name
- NCT03996356
- Testing
- No study intervention - observational study
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Cwm Taf University Health Board (NHS)
Neuropsychiatric Symptom
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment…
- Trial name
- DIAMOND (NCT07791212)
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- King's College London